Paladin Pharma

What Paladin Pharma does

Paladin Pharma is a Canadian specialty pharmaceutical company headquartered in Montreal, Quebec (Saint Laurent), that commercializes branded prescription medications across multiple therapeutic areas including neurology, infectious disease, urology, women's health, dermatology, transplant medicine, sleep disorders, and allergy. The company maintains a portfolio of approximately 17 branded products sourced primarily through in-licensing arrangements with global developers, including XCOPRI (cenobamate for epilepsy), Wakix (pitolisant for narcolepsy), Xydalba (dalbavancin antibiotic), Envarsus PA (once-daily tacrolimus for transplant patients), XIAFLEX (collagenase for Peyronie's disease and Dupuytren's contracture), Movapo (apomorphine for Parkinson's disease), WYNZORA (topical psoriasis treatment), Estring (estradiol vaginal ring), and Penthrox (methoxyflurane analgesic). The underlying technology is the branded specialty pharmaceutical molecule itself; Paladin does not conduct discovery research but rather holds Health Canada approvals and provincial reimbursement listings for in-licensed compounds.

The business model is a licensing-and-commercialization platform: Paladin acquires Canadian commercialization rights from upstream innovators (e.g., Bioprojet, Helsinn, ADVANZ PHARMA, ARIAD Pharmaceuticals), secures regulatory approval and reimbursement, then distributes through direct customer service channels (toll-free phone, fax, email) and dedicated HCP portals to physicians, pharmacists, and hospitals across Canada. Revenue is generated through one-time license sales of pharmaceutical products; pricing is set indirectly through provincial drug reimbursement programs and private insurance rather than direct price disclosure. The company employs 51-100 staff and operates with bilingual (English/French) coverage appropriate for the Canadian market.

Paladin operated as an Endo, Inc. subsidiary (previously known as Paladin Labs Inc., founded 1996) until June 17, 2025, when Knight Therapeutics Inc. (TSX: GUD) completed its acquisition for approximately $107 million including inventory and contingent payments. The acquisition was strategically framed as expanding Knight's pan-American (ex-US) specialty pharmaceutical presence in Canada and Latin America. Post-acquisition, Paladin continues to operate as a branded portfolio within Knight, with customer service and medical information functions now routed through Knight's infrastructure.

Name

Paladin Pharma

Legal name

Paladin Pharma Inc.

Website

https://paladin-pharma.com

Company type

Private

Founded year

1996

Operating status

Acquired

Headcount range

51–100 employees

Short description

Paladin Pharma is a Montreal-based specialty pharmaceutical company that commercializes approximately 17 branded prescription medications across neurology, infectious disease, women's health, transplant, and dermatology via in-licensing, holding Health Canada approvals and provincial reimbursement. Acquired by Knight Therapeutics in June 2025 for $107 million.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)

Keywords

• Specialty pharmaceuticals
• Branded prescription drugs
• Canadian pharmaceutical distribution
• Therapeutic product licensing
• Specialty drug commercialization

Headquarters

HQ city

Saint Laurent

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Paladin Pharma generates revenue through the sale of specialty branded pharmaceutical products including prescription medications, topical treatments, injectable antibiotics, and other therapeutic products marketed in Canada.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Paladin Pharma is a Canadian specialty pharmaceutical company that commercializes a portfolio of branded prescription pharmaceutical products across multiple therapeutic areas, including neurology (epilepsy, Parkinson's disease, narcolepsy), infectious disease, dermatology (psoriasis), urology (transplant immunosuppression, kidney stones, Peyronie's disease), women's health, and allergy treatment. The company licenses or in-licenses products from international partners, secures Health Canada approvals, and distributes through direct sales channels to Canadian physicians, pharmacists, hospitals, and patients via prescription.

Product overview

Paladin Pharma is a specialty pharmaceutical company with a diverse portfolio of branded products across multiple therapeutic areas. The company offers a range of prescription medications including Estring® (hormone replacement), Penthrox® (analgesic), Pollinex®R (allergen immunotherapy), Prostin® E2 Vaginal Gel (obstetrics), Urocit®-K (urology), VagiSense® (diagnostics), WYNZORA® (dermatology), XCOPRI™ (neurology), Xydalba® (anti-infective), Wakix® (sleep disorders), Envarsus® PA (immunosuppression), Movapo® (neurology), XIAFLEX® (urology/dermatology), and various consumer health products. Paladin operates as an Endo, Inc. operating company and was acquired by Knight Therapeutics Inc. in June 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Estring® Estradiol vaginal ring for hormone replacement therapy in women, distributed via prescription in Canada.
• Penthrox® Methoxyflurane volatile liquid for inhalation used as an analgesic, restricted to healthcare professionals (HCPs only) in Canada and distributed through a dedicated HCP channel (penthrox.ca).
• Pollinex®R Modified ragweed pollen allergen tyrosine adsorbate suspension for injection used for allergen immunotherapy (allergy treatment).
• Prostin® E2 Vaginal Gel Dinoprostone vaginal gel used for labor induction in obstetrics.
• Urocit®-K Potassium citrate extended-release tablets used for kidney stone management in urology.
• VagiSense® Vaginal infection screening test for home use to detect vaginal pH changes associated with infection.
• WYNZORA® Topical treatment for psoriasis vulgaris approved by Health Canada, with Canadian rights obtained through Paladin asset acquisition.
• XCOPRI™ (cenobamate) Cenobamate tablets for the management of partial-onset seizures in adults with epilepsy, approved in Canada.
• Xydalba® (dalbavancin) Dalbavancin for injection, an antibiotic for treating bacterial infections including acute bacterial skin and skin structure infections.
• Wakix® (pitolisant) Pitolisant medication approved in Canada for the treatment of narcolepsy.
• Envarsus® PA (tacrolimus) Once-daily immunosuppressive therapy (tacrolimus prolonged-release tablets) for kidney and liver transplant patients.
• Movapo® (apomorphine) Apomorphine hydrochloride for patients with advanced Parkinson's disease, reimbursed in most Canadian provinces.
• XIAFLEX® Collagenase Clostridium Histolyticum injection for treating Dupuytren's contracture and Peyronie's disease.
• Unisom® Snore Relief Natural Health Product throat spray to relieve symptoms associated with snoring, launched in Canada.
• Iclusig (Ponatinib) Ponatinib for the treatment of leukemia, commercially distributed in Canada under an ARIAD partnership.
• Zincofax® Spray Topical spray product launched in Canada.
• Emtrix® Dermatological product launched in Canada for nail care treatment.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Knight Therapeutics Inc.coreStrategic or Co-development Partner · 17 June 2025Knight Therapeutics Inc. completed the acquisition of Paladin Pharma Inc. for approximately $107 million, including inventory and potential contingent payments. The acquisition aimed to expand Knight's presence in Canada and Latin America and enhance its growth trajectory.
• ADVANZ PHARMAcoreStrategic or Co-development Partner · 12 April 2021ADVANZ PHARMA and Endo announced a partnership for Paladin Labs to commercialize Xydalba (dalbavancin hydrochloride) in Canada. This partnership enabled Paladin to expand its infectious disease portfolio with this antibiotic treatment.
• Endo InternationalcoreOthers · 5 January 2021Endo International announced a licensing agreement for Paladin Labs Inc. to commercialize Abaloparatide in Canada. Paladin operated as an Endo operating company before being acquired by Knight Therapeutics.
• HelsinnminorStrategic or Co-development Partner · 31 July 2019Helsinn and Endo announced an agreement for Paladin Labs Inc. to commercialize Pracinostat in Canada. Pracinostat is a product being developed for oncology indications.
• BioprojetcoreStrategic or Co-development Partner · 25 July 2018Bioprojet and Endo jointly announced an agreement for Paladin Labs Inc. to commercialize Pitolisant in Canada. This led to the approval of Wakix (pitolisant) in Canada in June 2021 for the treatment of narcolepsy.
• ARIAD PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 10 June 2015ARIAD and Paladin announced a commercial distribution agreement for Iclusig (Ponatinib) in Canada. Paladin served as the commercial distribution partner for this oncology medication.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Valeo Pharma: Canadian specialty pharmaceutical company focused on prescription products across multiple therapeutic areas, also using in-licensing to build a Canadian brand portfolio.
• HLS Therapeutics: Canadian specialty pharma focused on CNS, cardiovascular and women's health; similar Canadian-centric distribution model and specialty branded-product strategy.
• Cipher Pharmaceuticals: Canadian specialty pharma commercializing branded prescription products via licensing — closely comparable in-licensing model, small headcount, and Canadian-market focus.
• ADVANZ PHARMA: Global specialty pharmaceutical company that partnered with Paladin for Xydalba in Canada; comparable specialty, hospital-focused pharma commercialization and licensing approach.
• Acerus Pharmaceuticals: Canadian specialty pharmaceutical company commercializing branded prescription products, overlapping with Paladin in specialty men's/urology and women's health categories.
• Knight Therapeutics: Pan-American (ex-US) specialty pharmaceutical company that acquired Paladin in 2025; mirrors Paladin's specialty-pharma in-licensing and commercialization model across Canada and Latin America.

Broad incumbents

• Endo Pharmaceuticals: Large diversified pharmaceutical company that previously owned Paladin as an operating subsidiary; comparable branded specialty/generics commercial business model at much larger scale.
• Bausch Health: Major Canada-headquartered specialty pharmaceutical company with branded specialty prescriptions across neurology, dermatology and women's health — broader portfolio but overlapping therapeutic categories.
• Apotex: Largest Canadian-based pharmaceutical manufacturer with generics and some specialty branded offerings; broad incumbent against which Paladin competes for Canadian physician share.

Emerging players

• Theratechnologies: Canadian specialty biopharma commercializing niche therapies including HIV and oncology; similar small-cap Canadian specialty model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paladin Pharma